51598-76-6

Basic information

• Product Name: 6-METHYLNICOTINOYL CHLORIDE
• Synonyms: 6-METHYLNICOTINOYL CHLORIDE;3-Pyridinecarbonyl chloride, 6-methyl- (9CI);3-Pyridinecarbonyl chloride, 6-Methyl-;6-methyl-3-Pyridinecarbonyl chloride
• CAS NO: 51598-76-6
• Molecular Formula: C₇H₆ClNO
• Molecular Weight: 155.58
• Product Categories: ACIDHALIDE
• Mol File: 51598-76-6.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-METHYLNICOTINOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYLNICOTINOYL CHLORIDE(51598-76-6)
• EPA Substance Registry System: 6-METHYLNICOTINOYL CHLORIDE(51598-76-6)

Safety Data

• Hazardous Substances Data: 51598-76-6(Hazardous Substances Data)

Usage

General Description

6-METHYLNICOTINOYL CHLORIDE is a chemical compound derived from the molecule nicotine. It is commonly used in organic synthesis and pharmaceutical research as a building block for the production of various drugs and biologically active molecules. 6-METHYLNICOTINOYL CHLORIDE is a chlorinated derivative of 6-methylnicotinic acid and is known for its reactivity in reactions such as acylation and amidation. 6-METHYLNICOTINOYL CHLORIDE is valued for its role in the creation of new chemical entities and is employed in the development of pharmaceuticals and agrochemicals. It is important to handle this compound with care in a controlled laboratory environment due to its potentially hazardous properties.

Upstream product

• 3222-47-7 6-methylnicotinic acid 

Downstream Products

• 5470-70-2 Methyl 6-methylnicotinate 
• 1076692-17-5 6-methyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl] nicotinanilide monohydrochloride 
• 1211583-88-8 2-fluoro-6-methylpyridine-3-carboxylic acid 
• 221615-72-1 1-(6-methyl-3-pyridinyl)-2-[4-(methyl sulfide)phenyl]ethanone 
• 1448612-16-5 2-[1-(4-bromophenyl)cyclobutyl]-4-(6-methyl-3-pyridyl)thiazole 
• 40337-65-3 2-bromo-1-(6-methylpyridin-3-yl)ethan-1-one 
• 1333404-75-3 tert-butyl N-[3-[1-(3-benzyl-4-oxothieno[3,2-d]pyrimidin-2-yl)propyl-(6-methylpyridine-3-carbonyl)amino]propyl]carbamate 
• 676533-42-9 6-methyl-N-(2-methylcyclohexyl)nicotinamide 
• 676533-43-0 6-methyl-N-(4-methylcyclohexyl)nicotinamide 
• 36357-38-7 1-(6-methyl-pyridin-3-yl)-ethanone 
• 732245-99-7 5-isocyanato-2-methylpyridine 
• 64038-04-6 6-methyl-nicotinoyl azide 

Relevant articles and documents

Catalytic Deoxygenative Coupling of Aromatic Esters with Organophosphorus Compounds

We have developed a deoxygenative coupling of aromatic esters with diarylphosphine oxides/dialkyl phosphonates under palladium catalysis. In this reaction, aromatic esters can work as novel benzylation reagents to give the corresponding benzylic phosphorus compounds. The key of this reaction is the use of phenyl esters, an electron-rich diphosphine as a ligand, and sodium formate as a hydrogen source. Arylcarboxylic acids were also applicable in this reaction using (Boc)2O as an additive. Palladium/dcype worked to activate the acyl C-O bond of the ester and to support the reduction with sodium formate.

Nickel-Catalyzed Oxidative Decarboxylative Annulation for the Synthesis of Heterocycle-Containing Phenanthridinones

A nickel-catalyzed oxidative decarboxylative annulation reaction of simple benzamides and (hetero)aromatic carboxylates has been developed. This reaction provides access to a large array of phenanthridinones and their heterocyclic analogues, highlighting the utility and versatility of oxidative decarboxylative coupling strategies for C-C bond formation.

NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS

The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.